- Trial phase
- Approved (Accelerated Approval)
- Time to market
- Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
- Why 4/10
- VOCERYQ received FDA accelerated approval on October 30, 2026, resolving the defining binary catalyst. As an approved, marketed drug with no pending regulatory decision (PDUFA or pivotal readout), the next catalysts are commercial execution and a confirmatory study protocol, which are not hard binary events. ImpactScore is therefore 4 per the rubric.
With the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
Price Chart
Executive Summary
VOCERYQ (INO-3107) is Inovio Pharmaceuticals' first FDA-approved product, granted accelerated approval on October 30, 2026 for recurrent respiratory papillomatosis (RRP), a rare HPV-caused airway disease that typically requires repeated surgeries. It is the first plasmid DNA-based immunotherapy ever approved in the U.S., targeting HPV types 6 and 11. The approval was based on a 32-patient Phase 1/2 open-label study in which 27% of evaluable patients required no surgical intervention for 12 months. Inovio faces a narrow commercial window: cash runway extends only into late Q1 2027, it must compete with Precigen's already-marketed Papzimeos, and continued approval depends on a confirmatory study. The stock surged ~270% pre-market on the news, reflecting the platform validation but also raising questions about whether commercial upside is already priced in.
How It Works
VOCERYQ is a DNA-based immunotherapy (a plasmid, a small circle of DNA) that is injected into muscle and delivered with a brief electrical pulse (electroporation) to help cells absorb it. Once inside cells, the DNA instructs them to produce proteins from HPV types 6 and 11, the viruses that cause RRP. This trains the immune system's T cells to recognize and attack HPV-infected cells in the airway, reducing the growths that require repeated surgery.
Trial Status
Approval was based on the completed Phase 1/2 RRP-001 study (NCT04398433), an open-label trial of 32 adults with RRP who had at least two surgeries in the prior year. Of 26 efficacy-evaluable patients (with >=3 prior surgeries), 27% (7/26) required no surgical excision for 12 months post-treatment, and 72% saw a 50-100% reduction in surgeries in Year 1. Long-term follow-up data through Year 2 showed sustained reduction in surgical burden. A confirmatory post-approval study is required, with a draft protocol due to the FDA by end of 2026 and final alignment by mid-2027.
The Two-Sided Case
Upcoming Catalysts
- Confirmatory study draft protocol submission to FDA (due end of 2026)
- Confirmatory study final protocol alignment with FDA (expected mid-2027)
- Initial commercial availability and ordering (within ~60 days from Oct 30, 2026)
- Full commercial launch and field deployment (Q1 2027)
- Q3 2026 earnings report (scheduled Nov 9, 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INOVIO PHARMACEUTICALS, INC. 8-K INO ·Originating report